WLH-132

WLH-132 is a small molecule chemotherapy agent currently in development by Shenzhen Wanle Pharmaceutical (Wanle Pharmaceutical). It is part of a series of oncology research projects focused on treating a broad spectrum of malignancies, including solid tumors and hematologic cancers. Specifically, the drug is being developed for indications such as bladder cancer, breast cancer, leukemia, lymphoma, liver cancer, and digestive system cancers including gastric and colorectal cancer. As a chemotherapy agent, WLH-132 is intended to inhibit the proliferation of cancer cells, although its specific molecular target and clinical development phase have not been publicly disclosed by the developer.